ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

被引：0
|
作者：
Diels, J. [1 ]
Schubert, A. [2 ]
Hamilton, G. [3 ]
Canovatchel, W. [4 ]
机构：
[1] Janssen Res & Dev, Beerse, Belgium
[2] Janssen Cilag Poland, Warsaw, Poland
[3] Janssen Cilag Ltd, High Wycombe, Bucks, England
[4] Janssen Global Serv LLC, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2048
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB8
引用
收藏
页码：A598 / A598
页数：1
相关论文
共 50 条
  • [1] Characteristics of Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Therapy with Canagliflozin
    Martin, Silas C.
    Henk, Henry J.
    Chow, Wing
    [J]. DIABETES, 2014, 63 : A307 - A307
  • [2] Achievement of Diabetes-related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Blonde, Lawrence
    Woo, Vincent
    Mathieu, Chantal
    Yee, Jacqueline
    Vijapurkar, Ujjwala
    Meininger, Gary
    [J]. DIABETES, 2014, 63 : A284 - A284
  • [3] Triple-Goal Achievement in Patients with Type 2 Diabetes Mellitus (T2DM) Improves Clinical Outcomes
    Shi, Qian
    Shi, Lizheng
    Fonseca, Vivian
    [J]. DIABETES, 2015, 64 : A236 - A236
  • [4] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Pfeifer, Michael
    Townsend, Raymond
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Ren, Jimmy
    [J]. DIABETES, 2016, 65 : A303 - A303
  • [5] Psychosocial adjustment and outcomes of glycaemic control with basal insulin therapy in patients with type 2 diabetes mellitus (T2DM)
    Tanenberg, R. J.
    Zhang, Q.
    Zisman, A.
    [J]. DIABETOLOGIA, 2007, 50 : S435 - S436
  • [6] Glycaemic control and pregnancy outcomes in women with Type 2 diabetes mellitus (T2DM)
    Pang, W. H.
    Tan, Z.
    Todd, D.
    Halliday, M.
    Gill, F.
    Rhoads, M.
    Sathiskumar, P.
    Gallagher, A.
    de Chazal, R.
    Lawrence, I. G.
    [J]. DIABETIC MEDICINE, 2008, 25
  • [7] Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM)
    Shi, Qian
    Liu, Shuqian
    Krousel-Wood, Marie
    Shao, Hui
    Fonseca, Vivian
    Shi, Lizheng
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 140 : 45 - 54
  • [8] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Usiskin, Keith
    Leiter, Lawrence A.
    Forst, Thomas
    Polidori, David
    Xie, John
    Sha, Sue
    [J]. DIABETES, 2014, 63 : A284 - A284
  • [9] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)
    Tamborlane, William
    Polidori, David
    Di Prospero, Nicolas
    [J]. DIABETES, 2017, 66 : A371 - A371
  • [10] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nyirjesy, Paul
    Sobel, Jack
    Fung, Albert
    Gassmann-Mayer, Cristiana
    Ways, Kirk
    Usiskin, Keith
    [J]. DIABETES, 2013, 62 : A276 - A276
12345